Immunohistochemistry and gene profiling assays have suggested the presence of a “T-cell-inflamed tumor microenvironment,” with an abundance of chemokines and an IFN-γ signature, to correlate with the clinical efficacy of immune checkpoint inhibitors in melanoma patients (21, 22). The gene discussed is IFNG; the disease is neoplasm.